Another first – Rethymic approved for a Rare Pediatric Immune Disorder treatment
Rethymic, a regenerative tissue based therapy is now approved by the US FDA for patients with congenital athymia. It took more than 25 years for its research and development at the Duke University School of Medicine. Enzyvant acquired the license in 2017 and suffered FDA rejection in 2019. For many it was a surprise rejection,…
News Views